Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

.

Extavia should be used with caution in patients with depression. Injection site necrosis has been reported in 4% of patients in controlled trials. Typically, injection site necrosis occurs within the first four months of therapy. Necrosis may occur at a single injection site or multiple injection sites. Patient understanding and use of aseptic self-injection techniques and procedures should be periodically reevaluated, particularly if injection site necrosis has occurred. Anaphylaxis has been reported as a rare complication of interferon use. Other allergic reactions have included dyspnea, bronchospasm, tongue edema, skin rash, and urticaria.

The rate of flu-like symptom complex was approximately 57% in the four controlled clinical trials. The incidence decreased over time, with only 10% of patients reporting flu-like symptom complex at the end of the studies. Monitoring of complete blood and differential white blood cell counts, platelet counts and blood chemistries, including liver function tests, are recommended at regular intervals.

The most commonly reported adverse reactions are lymphopenia, injection site reaction, asthenia, flu-like symptom complex, headache and pain. Based on all the available evidence, the relationship between antibody formation and clinical safety and efficacy is not known. Female patients should be warned about the potential risk to pregnancy. The mechanism of action of interferon beta-1b in patients with multiple sclerosis is unknown. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. Patients should be advised of the importance of rotating injection sites.

* Novartis gained the rights to seek approval for its own branded version of interferon beta-1b through agreements with Bayer Schering, the company that markets Betaseron.

Betaseron is marketed under the name of Betaferon(R) outside
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced the ... of Warburg Pincus LLC, to the Amgen Board of Directors. ... Hassan and the deep, global experience he brings in ... A. Bradway , chairman and chief executive officer of Amgen. "Fred,s ... Amgen well." Mr. Hassan has been Partner and ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... announces that a new market research report ... IP Overview – "Monoclonal Antibodies ... http://www.reportlinker.com/p0296354/IP-Overview-–-"Monoclonal-Antibodies-against-digestive-system-cancers"-Patent-Landscape-2010.html ... digestive system cancers, monoclonal antibody-based therapies have ...
... MORRISVILLE, N.C., Sept. 21 During the recent ... the European Association of Cardiac Thoracic Surgeons in ... Surgery from University Medical Center in Ljubljana, Slovenia ... professionals to think differently about existing atrial fibrillation ...
Cached Medicine Technology:Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010 2Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010 3Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation 2Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation 3
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company based in Schenectady, N.Y., ... 16 percent year-over-year for the first six months ended June 30, 2015 compared with ... to beat last year’s record-revenue mark of $10.4 million. , “We know what our ...
(Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley Associates , ... the 2015 Aster Awards national competition for a marketing communications campaign created for ... surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze Award was ...
(Date:7/31/2015)... ... July 31, 2015 , ... Like nearly every other form of surgery, ... upgraded, made more effective and less intrusive and painful. Leading these advances in ... Dr. Loria currently stands as the only doctor in the United States who ...
(Date:7/31/2015)... York, NY and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm ... photo op. , Glancing out of the window, he recalled that his equipment was ... 215 Chrystie Street tower, he jumped out of bed. , The photo speaks for ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic ... National Soccer Team will face the Australia Women's National Team in two separate friendly ... Field in Detroit and the second match will occur in Birmingham, Alabama at Legion ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... developed and began implementing a Strategic Plan,while facilities ... to,improve patient safety while implementation of Act 52 ... HARRISBURG, Pa., April 30 The Pennsylvania,Patient ... outlining,its Strategic Plan that aligns its activities more ...
... Inc.,(Nasdaq: IFLG ), a leading technology provider ... industries, will host a,conference call with the financial ... Company,s First Quarter 2008 financial results and provide ... ), Interested parties may participate in ...
... announces,the launch of a new microsite featuring its ... to complement Baxa direct sales efforts,and features an ... the site,s interactive tools to explore MedBoard features,and ... asked,questions and key product attributes., "The microsite ...
... vaccines for new flu strains, other health threats ... Researchers have devised a rapid and efficient method ... called monoclonal antibodies, which mark and neutralize foreign ... accelerate the traditionally challenging task of generating human ...
... release is also available in French . ... older teens dont necessarily eat a healthier diet than ... no link between body mass index (BMI) values and ... study of 900 Vancouver-area teenagers in Grades 10 through ...
... April 30 T.J. Harkins, President of,TriMix Laboratories ... dysfunction product, TriMix-gel(TM), will be presented at a,moderated ... May 20, 2008 in Orlando, FL. The study ... FAILED PHOSPHODIESTERASE INHIBITORS., The abstract evaluates TriMix-gel ...
Cached Medicine News:Health News:Patient Safety Authority Issues Annual Report for 2007 2Health News:Patient Safety Authority Issues Annual Report for 2007 3Health News:Patient Safety Authority Issues Annual Report for 2007 4Health News:Patient Safety Authority Issues Annual Report for 2007 5Health News:Patient Safety Authority Issues Annual Report for 2007 6Health News:Patient Safety Authority Issues Annual Report for 2007 7Health News:Patient Safety Authority Issues Annual Report for 2007 8Health News:Patient Safety Authority Issues Annual Report for 2007 9Health News:Patient Safety Authority Issues Annual Report for 2007 10Health News:Patient Safety Authority Issues Annual Report for 2007 11Health News:Patient Safety Authority Issues Annual Report for 2007 12Health News:Patient Safety Authority Issues Annual Report for 2007 13Health News:Patient Safety Authority Issues Annual Report for 2007 14Health News:Patient Safety Authority Issues Annual Report for 2007 15Health News:Patient Safety Authority Issues Annual Report for 2007 16Health News:Patient Safety Authority Issues Annual Report for 2007 17Health News:Patient Safety Authority Issues Annual Report for 2007 18Health News:InfoLogix to Report First Quarter Results on April 30, 2008 - Conference Call Information 2Health News:Baxa Launches Microsite Featuring the MedBoard(TM) Medication Tracking System 2Health News:Researchers Develop Quick Way to Create Human Antibodies 2Health News:Researchers Develop Quick Way to Create Human Antibodies 3Health News:Physical activity, healthy eating and BMI not linked in older teens: study 2Health News:TriMix-gel vs Viagra, Levitra, Cialis Data to Be Presented at AUA 2
... The Research Family includes fixed-volume, adjustable-volume, ... the electronic Eppendorf Research pro Pipette. ... these compact, high-performance pipettes have earned ... suited for use with original Eppendorf ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: